Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 Year experience at Rizzoli Institute, Italy

Gaetano Bacci, Alessandra Longhi, Franca Fagioli, Antonio Briccoli, Michela Versari, Piero Picci

Research output: Contribution to journalArticle

Abstract

Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different protocols of neoadjuvant chemotherapy. The rate of limb salvage increased from 20% to 71%. The 5-year event-free survival (EFS) and overall survival (OS) were 57% and 66%, respectively. The 10-year EFS and OS were 52% and 57%, respectively, and the results significantly correlated with serum alkaline phosphatase levels; the type of chemotherapy (adjuvant vs neoadjuvant); and with histologic response to pre-operative treatment. Aggressive chemotherapy and surgery could cure about the 60% of patients with osteosarcoma of the extremity. However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended.

Original languageEnglish
Pages (from-to)2836-2845
Number of pages10
JournalEuropean Journal of Cancer
Volume41
Issue number18
DOIs
Publication statusPublished - Dec 2005

Keywords

  • Chemotherapy
  • Follow-up
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 Year experience at Rizzoli Institute, Italy'. Together they form a unique fingerprint.

  • Cite this